Pharmaceutical

Thermo Fisher’s Oncomine gains FDA approval as brain tumor diagnostic

As a companion diagnostic, Oncomine will be used to identify patients eligible for treatment with Servier’s Voranigo.

Oct 22, 2024 - 04:00
Thermo Fisher’s Oncomine gains FDA approval as brain tumor diagnostic
As a companion diagnostic, Oncomine will be used to identify patients eligible for treatment with Servier’s Voranigo.
Read the original article

Tags:

Previous Article

Cambridge University and GSK sign immunology R&D collaboration

Next Article

AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Why prefilled vial capacity is key to a competitive edge in pharmaceuticals manufacturing 

Why prefilled vial capacity is key to a competitive edg...

Sep 11, 2023

Attralus set for amyloidosis asset’s European orphan designations

Attralus set for amyloidosis asset’s European orphan de...

Jul 30, 2024

‘The drug bust paradox’: Study shows opioid deaths double after police action

‘The drug bust paradox’: Study shows opioid deaths doub...

Jun 14, 2023